The regulatory path for rescheduling psychedelics for healthspan

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

As psychedelics emerge as tools for cognitive resilience and healthspan, Devin Partida looks at how outdated drug policy collides with geroscience.

Psychedelics are reemerging in modern medicine, backed by early-stage research exploring their therapeutic effects beyond mental health. Once sidelined by stigma and strict drug policies, compounds like psilocybin and LSD are now being studied for their potential to improve cognitive resilience and support neural regeneration.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Guest Contributor

A guest contributor joins us to add to the longevity conversation!

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE